Hepatocellular carcinoma (HCC) is the most common type of liver cancer, often arising in individuals with chronic liver diseases such as cirrhosis or hepatitis. The HCC Methylation trial focuses on the early detection of Hepatocellular Carcinoma (HCC) and the development of methodology for the early detection of HCC.
The purpose is to develop a method to measure methylated DNA as a biomarker of HCC. This study will examine novel Methyl 10 liquid biopsy approach which will have utility for detection of very early HCC. To participate in the trial, all individuals must meet the following criteria and be able to do the following actions:
- Be 18 years of age and older.
- If you have active HCC, be able to prepare for an ablation and collect a post-sample every 3 months.
- If you do not have HCC but are at high risk, be able to collect a post-sample every 6 months.
To learn more please email: kianakhbari@arizona.edu